Bayer (BAYN) Makes SUNHARBO Available in the U.S. at $748.50 per 30-Day Supply

Bayer (BAYN) has launched SUNHARBO in the U.S. at $748.50 per 30-day supply. The drug's approval was based on Phase 3 trial results showing a 6.2% stroke rate versus 8.4% with placebo. Sales data is not yet available.

Original reporting
Published Nov 20, 2026, 2:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 20, 2026, 2:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Bayer (BAYN) Makes SUNHARBO Available in the U.S. at $748.50 per 30-Day Supply — source image
Decision brief

The 30-second read

$BAYN.DENeutralHigh
01

Why it matters

The launch price sets a premium benchmark in the stroke‑prevention market, creating both revenue upside and uptake risk.

02

Market read

First report of a new, high‑priced drug launch from a major pharma company.

03

What to watch

Potential insurance coverage decisions and competitive pipeline drugs.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Bayer's SUNHARBO (asundexian) received FDA approval after Phase 3 showed reduced ischemic stroke rates versus placebo.

Company-level read

Ticker impact

$BAYN.DENeutralHigh confidence
Context

Bayer announced its stroke‑prevention drug SUNHARBO is now available in the U.S. with a list price of $748.50 per 30‑day supply.

Expected impact

likely pressure as the market prices in the costly new drug launch

Evidence & confidence

Bayer is a large‑cap pharma; a new, expensive product can affect revenue expectations and stock valuation.

Market effects

May influence other stroke‑prevention drug makers and biotech investors.

U.S. pharma market sees a new high‑priced entrant.

Limited to Bayer and its peers; no broad market shift expected.

Counterpoint

If reimbursement is secured, the drug could boost Bayer's earnings despite the high price.

Key entities

  • Bayer

    German pharmaceutical giant launching SUNHARBO in the U.S.

Related articles

$BAYN.DEMed

Deutsche Bank raises Bayer stock price target on stronger earnings

Deutsche Bank raised its price target on Bayer AG to EUR65.00 from EUR60.00, maintaining a Buy rating. The firm increased its 2026 adjusted EBITDA forecast to EUR10,060 million, driven by stronger pharmaceutical performance. Bayer's stock has surged 109% over the past year, trading at $15.91. The company reported Q3 2026 earnings of $0.0868 per share on revenue of $11.26 billion, missing expectations but raising full-year guidance.